Patent Information Users Group, Inc.
n We’re o
s
m a d
A
a h t r e
B y b o t o h p
” i PIUG 2011 Biotechnology Meeting t s A focused! & e v li O “
February 9, 2011
Genentech Campus BizInt Smart Charts South San Francisco, California for Patents 3.4
BizInt Smart Charts for Patents helps you create reports combining search results from gene sequence databases (GenomeQuest and USGENE on STN) with results from patent and non-patent literature Congratulations to Remy – searches. Dachshund Club of America Triathlon Dog of 2010! BizInt Smart Charts for Patents Version 3.4 adds: • support for LexisNexis TotalPatent and Orbit.com, • features to make it easier to edit reports, and • more sources for full-text links. We’re also working hard on BizInt Smart Charts Reference Rows™, with an exciting new capability to combine data from different records into a single “Reference Row” row in your report.
Visit our website www.bizcharts.com to learn more about the latest developments in BizInt Smart Charts for Patents!
650 North Costello Pl Orange, CA 92869 USA 1.714.289.1000 TEL 1.714.744.1316 FAX www.bizcharts.com Silver Sponsor of the PIUG Biotechnology Meeting
For more information, please visit our website - www.bizcharts.com Meeting Book prepared by BizInt Solutions, Inc., a proud sponsor of the 2011 Biotechnology Meeting PIUG 2011 Biotechnology Meeting Wednesday, February 9, 2011 Genentech, South San Francisco, CA
7:30 am 8:15 am Registration and Breakfast 8:15 am 8:30 am Welcome to Genentech Atulya Agarwal, Head of Patents, Oncology Welcome to the PIUG 2011 Biotechnology Meeting Monica Weiss-Nolen, Program Chair 8:30 am 9:05 am Potent Antibody Drugs by Design Paul Carter, Genentech 9:05 am 9:40 am Biosimilars: New Decisions and New Opportunities Michelle Lewis, ZymoGenetics 9:40 am 10:15 am Sequence Business Process and Frequently Asked Questions on Sequence Compliance Issues Dave Nguyen, USPTO 10:15 am 10:45 am Break – Exhibits Open 10:45 am 11:20 am Search and Examination for Biotech Applications in JPO Takashi Saku, JPO 11:20 am 12:00 noon Beyond Gene Patenting Turmoil: A Reality Check for Patent Protection of Biosequences in Europe Luca Falciola, Genfit 12:00 pm 1:30 pm Lunch and Exhibits 1:30 pm 2:05 pm Advice to Beginner and Intermediate Searchers for a Biotechnology Patent Search Ken Hoppe, Science IP 2:05 pm 2:40 pm Comparison of USGENE vs. GQ-PAT and Geneseq Fanny Coignard, PDG Biotechnology Information Working Group Chair 2:40 pm 3:10 pm Break – Exhibits Open 3:10 pm 3:45 pm Comprehensive Search Strategy for Genomics-Based Intellectual Property Protection Steve Chappell Mitchell, TPR 3:45 pm 4:20 pm Improving FTO Patent Analysis- Focusing Results Using Scientific Analysis Barbara Miller, Novartis 4:20 pm 5:00 pm Biologics - Searching Patent Classes at the USPTO, WIPO, EPO, and JPO James L. Grant Concluding Remarks Doreen Alberts, Planning Committee Chair 5:00 pm 5:30 pm Exhibits and Networking 5:30 pm Adjourn Patent Information Users Group, Inc.
PIUG 2011 Biotechnology Meeting
New Biologics: Proteins & Beyond
February 9, 2011
Genentech Campus 611 Gateway Blvd. Building 83 South San Francisco, CA 94080
Meeting Book prepared by BizInt Solutions, a proud sponsor of the PIUG 2011 Biotechnology Meeting and developer of BizInt Smart Charts for Patents 1 2011 PIUG Biotechnology Meeting
Message from the Chair Anthony Trippe, PIUG Chair
Welcome to the 2011 PIUG Biotechnology Meeting! We also need to thank our sponsors who make meetings like this possible. We appreciate the generous support As I was starting to write this message I was reminded of Genome Quest, STN, Dialog, Dolcera, Quosa and of the Bee Movie starring Jerry Seinfeld which my family Search Technology in supporting PIUG and helping and I watched recently. There was a part of the movie sponsor this meeting. Please take some time today to where Seinfeld’s bee says, “We bees get behind a talk to each of them (they are all long time PIUG spon- fellow.” To which his fellow bees respond by shouting sors) and let them know how much we appreciate their out “Black and yellow!”. This may seem like a strange assistance. way to welcome attendees to a PIUG meeting but stay with me since watching this event come together showed Finally, on the theme of getting behind a fellow we me something special about PIUG and it’s volunteers. had a special circumstance come up this year where we needed some help with our meeting books at the Meetings like this one only come together because a lot last minute and our good friends at BizInt Smart Charts of people work together towards a common goal. A responded to that need and helped us during a difficult lot of little jobs become large tasks and in the end what situation. They really stepped up for PIUG and we owe is accomplished by the group can be truly astonishing. them a debt of thanks. That was the case for this meeting and culminates in the tremendous program you are about to enjoy. So a lot of people worked together to make the meeting in San Francisco possible. It is just another example of It started with the idea that even though this is the fifth what makes PIUG special, the fact that we get behind time PIUG has held this meeting, it is the first time that it and support one another. is being held outside of Boston. We have lots of people to thank for the move but we especially need to thank Along those lines I also want to thank Allison Taylor for Ruben Diaz and Genentech for volunteering their facil- all her efforts on behalf of PIUG. I hope you know that ity for the meeting. Ruben did a tremendous amount of all of us are behind you and your family and we appre- work with the Program Committee and the management ciate everything you do. at Genentech to make sure we could all meet together. Enjoy the meeting, Speaking of the Program Committee, we also need to thank Monica Weiss-Nolan for Chairing this important Tony activity and her entire committee for putting together such a wonderful program. During the meeting we Program Committee: will be hearing from representatives from not just one, but two national patent offices, and PIUG would like to Monica Weiss-Nolen (Chair), Ruben Diaz, Alice thank JPO and the USPTO for sending speakers. While Goshorn, Diana Louden, Qin Meng, Elyse Turner it is always exciting to hear from the patent offices we also have a tremendous collection of speakers from the Planning Committee: Biotech industry and from our ranks who will be provid- Planning Chair: Doreen Alberts ing us with insight and practical knowledge that we can take back to our roles in our respective companies. Evaluation: Sian Griffiths Fundraising: Christine Geluk, Helen Oen We also had volunteers helping with website arrange- ments, registration, travel, evaluation, fundraising and Meeting Book: Alison Taylor, Diane Webb planning. The complete list of volunteers is provided Registration: Ken Koubek, Moninder Tank, Kim Spytek below and we especially need to thank Doreen Alberts Web Pages: Rick Williams, Tom Wolff for taking on the responsibilities of Planning Chair for the meeting. Doreen made our hotel arrangements and supervised most of the details of the meeting for all of us to enjoy. Putting on meetings like this are a lot of responsibility and Doreen has done a fantastic job with her entire team. 2 SPONSORS TABLE OF CONTENTS
Table of Contents
Meeting Agenda Inside Front Cover PIUG Officers 3 Sponsors 4-5 Speaker Abstracts & Biographies 6 Morning Session 6 Afternoon Session 16 Attendee List 26-27 PIUG Information 28
PIUG Officers
Chair, 2010–2012 Anthony Trippe 3LP Advisors (614) 787-5237 tony @ piug.org Vice Chair, 2010–2012 Denise Fobare-DePonio Amgen, Inc. (805) 447-6618 dfobare @ amgen.com Immediate Past Chair Cynthia Barcelon Yang Bristol Myers Squibb (609) 818-5515 Cynthia.Yang @ bms.com Secretary, 2010–2012 Jim Brown FIZ Karlsruhe (302) 376-6425 Jim.Brown @ fiz-k.com Treasurer, 2010–2012 Ken Koubek Koubek Consulting Svcs (302) 252-6045 KennethKoubek @ comcast.net Director-At-Large, 2008-2012 Heidi Stone Abbott (847) 937-2362 heidi.stone @ abbott.com Director-At-Large, 2010-2014 Diane Wian IFI Patent Intelligence (703) 323-0030 diane.wian @ wolterskluwer.com
3 2011 PIUG Biotechnology Meeting
gratefully acknowledges the generous support provided by our sponsors. The meeting would not exist without their support!
SILVER SPONSORS
BizInt Solutions GenomeQuest STN
BRONZE SPONSORS
Dolcera ProQuest/Dialog QUOSA Search Technology/Vantage Point
STN Ad
Sequences from patents – STN’s unrivalled coverage
STN® provides unrivalled coverage of biosequence data from patents made available by more than 50 authorities from all over the world. Only on STN can you search DGENE, CAS REGISTRYSM, USGENE® , and PCTGEN on a single platform. Sequence information has been intellectually analyzed and indexed. STN has everything you need – all in one place.
www.stn-international.com
STN is jointly operated by FIZ Karlsruhe, Germany, and Chemical Abstracts Service, USA.
4 Comprehensive, Online Patent Search. www.GenomeQuest.com Open For Discovery
TM
Patent Workflow Solutions will VantagePoint is a powerful desktop text-mining streamline your Intellectual Property tool that helps you quickly analyze and navigate and related processes! through large volumes of structured text to see patterns and relationships. • Automated patent retrieval from major patent databases. Competitive Technical Intelligence Management of “Open Innovation” • Easily create patent archives, with Patent analysis full-text searchable patent files Intellectual property management and metadata. Research & technology management • Simple and fast team access to your document, full-text article, Discover why many of today’s Fortune and patent archives, including 100 companies use VantagePoint to help report templates and alerts. them succeed.
Visit QUOSA’s table display at the PIUG Biotech meeting or contact John Mate at 410-268-4729 or [email protected] Turning Information into Knowledge www.theVantagePoint.com QUOSA, Inc. 1050 Winter Street, Suite 1000 Waltham, MA 02451
5 2011 PIUG Biotechnology Meeting
Morning Session
8:30 am – 9:00 am
Potent Antibody Drugs by Design
by Paul Carter, Genentech
Abstract Antibodies have come of age as therapeutics since the late-1990s with 24 antibody therapeutics marketed in the USA and >240 additional antibodies in clinical development. The focus of this presentation is the creation of even better next generation antibody drugs - a major area of interest in the field. The rationale to develop better even antibody therapeutics comes from a convergence of clinical, scientific, and commercial considerations in conjunction with technological advances that provide the tools to do so.
Biography Dr. Carter has 25 years of experience in biotechnology: Genentech (1986-2000 and 2010-present), Immunex/Amgen (2000-2003), Seattle Genetics (2003-2008) and VLST (2008-2009). Dr. Carter’s accomplishments in drug development include initiating the antibody humanization program at Genentech and co-inventing Herceptin®, a humanized antibody approved by the FDA for the treatment of HER2-overexpressing breast and gastric cancers. He is an inventor or co-inventor on 25 issued US patents. Dr. Carter has authored or co-authored 95 scientific publications that together have been cited >7,000 times. Dr. Carter received a B.A. in Natural Sciences from Cambridge University in 1982. He obtained a Ph.D. in 1986 under Sir Gregory Winter, Ph.D., F.R.S. at the MRC Laboratory of Molecular Biology in Cambridge. From 1986-1989 Dr. Carter was a Postdoctoral Fellow with Dr. James A. Wells at Genentech.
Contact Information [email protected]
6 SPONSORS MORNING SESSION
Potent Antibody Drugs by Design by Paul Carter, Genentech
7 2011 PIUG Biotechnology Meeting
Morning Session
9:05 am – 9:40 am
Biosimilars: New Decisions and New Opportunities
by Michelle Lewis, ZymoGenetics
Abstract The enactment of the legislative basis for biosimilar approval in March 2010 has brought some clarity to this area for those involved in the biotechnology industry. However, details about the specific procedures, the specific standards to be applied, and the ultimate impact of biosimilars on current and future products remain uncertain. During the maturation of the biosimilar approval process biotechnology industry leaders will face new decisions - decisions, if to be made intelligently, that will require accurate information about their products, their competitor’s products, and the involved intellectual property coverage and approval histories. This presentation will examine new decisions related to biosimilars that will be faced by management in the coming years and the type of information that will be required to make informed choices at these junctures. If armed with correct information, biotechnology companies will be able to seize the new opportunities presented by the biosimilar approval process and use it to expand the choices available to patients relying on biologic treatments.
Biography Michelle L. Lewis is a Senior Patent Attorney at ZymoGenetics, Inc., a biotechnology company located in Seattle, Washington which recently became a wholly owned subsidiary of Bristol-Myers Squibb. She has a Masters degree in Genetics from Columbia University and a biology degree from Duke. She began her patent career as an Examiner at the United States Patent Office in the Complex Biotechnology Arts. After leaving the office and working as a patent agent for several years, she attended Rutgers-Newark Law School, graduating with honors. Following a stint in law firms as an associate, she joined ZymoGenetics where she has worked for eight years. At ZymoGenetics she drafts, prosecutes, and manages worldwide patent and agreement portfolios for a number of company projects. Beyond prosecution and transactional responsibilities, she routinely briefs management on recent developments in the biotech arena, such as biosimilars and the current challenges to the patentability of genes and diagnostics.
Contact Information [email protected]
8 MORNING SESSION
Biosimilars: New Decisions and New Opportunities by Michelle Lewis, ZymoGenetics
9 2011 PIUG Biotechnology Meeting
Morning Session
9:40 am – 10:15 am
Sequence Business Process and Frequently Asked Questions on Sequence Compliance Issues
by Dave Nguyen, USPTO
Abstract The presentation provides a brief overview of USPTO current sequence business process. The presentation then covers common sequence compliance issues and frequently asked questions related thereto.
Biography Mr. Nguyen is a graduate of the Virginia Polytechnic Institute and State University and Johns Hopkins University. He works at the U.S. Patent & Trademark Office, where he served as the supervisory patent examiner of Art Unit 1633 and TC 1600 Quality Assurance Specialist from 2004-2009. He currently manages the Patent Examination Art Unit 1634 directed to personalized medicine and pharmacogenetics, and serves as a specialist and coordinator for the Sequence Business Process. Mr. Nguyen’s current assignments in the agency include: * Supervisory Patent Examiner, Art Unit 1634 * Workgroup 1630 Hiring Program Coordinator * Co-Lead of SharePoint Business Process * Co-Lead of Automation & Sequence Business Process * Member of the Enhancing Technical Knowledge Between Examiners Working Group - Patents Process Reengineering Team
Contact Information [email protected]
10 SPONSORS MORNING SESSION
Sequence Business Process and Frequently Asked Questions on Sequence Compliance Issues by Dave Nguyen, USPTO
11 2011 PIUG Biotechnology Meeting
Morning Session
10:45 am – 11:20 am
Search and Examination for Biotech Applications in the JPO
by Takashi Saku, Japanese Patent Office
Abstract It will be explained how patent applications in biotechnology field are searched and examined in the Japan Patent Office. Especially, the methods for searching about DNA and protein sequence and the examination standards in biotech will be discussed.
Biography After I received B.A. and M.A. degrees in Biotechnology from University of Tokyo in Japan, I started my career at the Japan Patent Office (JPO) as a patent examiner in 2000. I have worked at the JPO almost 11 years, and examined a lot of patent applications related to biotechnology and medical science fields. During the period, I had a chance to work at the Examination Standard Office, and now I am in charge of deputy director of the Examination Policy Planning Office.
Contact Information [email protected]
12 SPONSORS MORNING SESSION
Search and Examination for Biotech Applications in the JPO by Takashi Saku, Japanese Patent Office
13 2011 PIUG Biotechnology Meeting
Morning Session
11:20 am – 12:00 pm
Beyond Gene Patenting Turmoil: A Reality Check for Patent Protection of Biosequences in Europe
By Luca Falciola, Genfit
Abstract Since mid 1990’s, genomic-based discovery was instrumental in expanding, and testing, the limits of institutional policies and industry practices on gene patenting. Relevant data on the actual impact of the extensive integration of genetic information within patent documents can be extracted by integrating IPC-, keyword-, and sequence-based search strategies that are developed and performed in accordance to the content and the search features of sequence-based and full-text patent databases. A case study on major trends on the content and the outcome of examination at EPO for biosequence- containing PCT applications that have been filed in the late 1990s-early 2000s is presented in parallel to major recent decisions of EPO Board of Appeals in this field. This analysis is intended to provide quantitative and qualitative elements, as well as some methodological tips, that may be helpful for evaluating patent situation and strategies associated to an R&D project, a technology, or a company, in presently changing economic and legal environments.
Biography Luca Falciola is Director for Intellectual Property at Genfit (Loos, France). He previously held positions at RiboVax Biotechnologies (Petit-Lancy, Geneva, Switzerland) as Director for Intellectual Property & Collaborative Research, and at Serono as Patent Information Specialist and Patent Attorney. Luca holds a PhD in applied genetics and has done post-doc research in molecular biology. He is Member of AIDB (Italian Association of Patent Searchers), wherein he acts as editor of “AIDB Newsletter” and as AIDB representative in the working group of CEPIUG (Confederacy of European Patent Information User Groups) on professional certification. He provided courses and presentations on methods for searching patent & scientific information.
Contact Information [email protected]
14 SPONSORS MORNING SESSION
Beyond Gene Patenting Turmoil: A Reality Check for Patent Protection of Biosequences in Europe By Luca Falciola, Genfit
15 2011 PIUG Biotechnology Meeting
Afternoon Session
1:30 pm – 2:05 pm
Advice to Beginner and Intermediate Searchers for a Biotechnology Patent Search
By Ken Hoppe, Science IP
Abstract As biotechnology patent information consultants, we bring together the three spheres of our experience, as scientists, information professionals, and patent specialists. We leverage that combined knowledge to answer questions such as: When to do a sequence search, key word search, or both? What type of sequence search? How to conduct information analysis? How much value-add is too much? My talk will present and explain answers to these questions, as encountered during the pre-interview, interview, pre- search, search, report, and “information analysis” stages.
Biography Ken is a Senior Searcher at Science IP®, the professional search service of Chemical Abstracts Service (CAS), a division of the American Chemical Society. Prior to joining CAS in 2007, Ken worked for 12 years in the pharmaceutical industry at Pfizer, where he conducted molecular biology research in drug discovery for six years and then provided patent and scientific information research for in-house patent attorneys for six years. Prior to his pharmaceutical industry experience, Ken worked in academic molecular biology research laboratories at Harvard Medical School, Beth Israel Hospital Boston, and the University of Connecticut Health Center’s Department of Biochemistry. Ken focuses on comprehensive biological and biosequence patent retrieval and analysis in support of patentability, freedom to operate, validity, infringement, and due diligence activities within the legal and corporate environment. Ken has a MS in biology.
Contact Information [email protected]
16 SPONSORS AFTERNOON SESSION
Advice to Beginner and Intermediate Searchers for a Biotechnology Patent Search By Ken Hoppe, Science IP
17 2011 PIUG Biotechnology Meeting
Afternoon Session
2:05 pm – 2:40 pm
Comparison of USGENE vs. GQ-PAT and Geneseq
By Fanny Coignard (Pfizer), PDG Biotechnology Information Working Group Chair
Abstract The Patent Documentation Group’s Biotechnology Information Working Group has conducted a series of studies to compare and evaluate patent sequence databases. Several sequences were searched on three different occasions (March 2008, March 2010 and December 2010) to find similar sequences from three well known sources: USGENE, GQ-PAT and GENESEQ. The results presented show interesting differences in content, coverage and database update.
Biography Fanny Coignard has a biotechnology engineer degree (~MSc) from the E.S.B.S. (Strasbourg University) and has recently obtained the Certificat d’Animateur en Propriete Industrielle (I.N.P.I.). Fanny has been working as a Patent Information Scientist in the GLobal Legal Information Science Team (GLIST) at Pfizer for 6 years. Fanny specializes in biotechnology related patent questions, including sequence analysis. Before joining Pfizer, Fanny worked as a research scientist for 6 years at Bristish Biotech (Oxford, U.K.), Epigene (Paris, France) and Exonhit Therapeutics (Paris, France) where she gained experience in molecular biology, cell biology, bioinformatics, and proteomics. This presentation is given on behalf of the Patent Documentation Group’s Biotechnology Information Working Group, which Fanny has been a member of since 2006.
Contact Information [email protected]
18 SPONSORS AFTERNOON SESSION
Comparison of USGENE vs. GQ-PAT and Geneseq By Fanny Coignard, PDG Biotechnology Information Working Group Chair
19 2011 PIUG Biotechnology Meeting
Afternoon Session
3:10 pm – 3:45 pm
Comprehensive Search Strategy for Genomics-Based Intellectual Property Protection
By Steve Chappell Mitchell, TPR International
Abstract A comprehensive genetic search strategy in Biotechnology includes sequence-based discovery and analysis at protein level, DNA level, and conceptual keyword/classification coding combinations. This talk in genomics-based intellectual property protection will cover considerations within this comprehensive method: * Caution when using percent identity in algorithms * Developing a process for dealing with confounding DNA genomic interspersed repeat comprised sequences * When using percent identity, defining uses of the differential mathematical models from KERR (GenePAST) and BLAST algorithms Sequence-based discovery is vital, and necessary to combine with conceptual, keyword, coding-based search approaches within a most comprehensive method.
Biography Steve Chappell Mitchell is the Director of Biotechnology and Genomic Services at Technology & Patent Research (TPR) International. Before joining TPR, Steve was Senior Information Scientist at Abbott Laboratories where his work with attorneys was recognized with the ‘President’s Award’. Steve’s successful experience as a cancer discovery scientist at Harvard University and Cedars Sinai/UCLA, and his participation on the Human Genome Project at CalTech, have provided him with firsthand knowledge of gene cloning and sequencing. Also, Steve’s numerous patented inventorships confirm him as being on the cutting edge of technology and the patent process. In intellectual property protection at TPR, Steve’s clients include most major pharmaceutical companies, and a large group of biotechnology companies and law firms worldwide.
Contact Information [email protected]
20 SPONSORS AFTERNOON SESSION
Comprehensive Search Strategy for Genomics-Based Intellectual Property Protection By Steve Mitchell, TPR
21 2011 PIUG Biotechnology Meeting
Afternoon Session
3:45 pm – 4:20 pm
Improving FTO Patent Analysis- Focusing Results Using Scientific Analysis
By Barbara Miller, Novartis Institutes for BioMedical Research, Inc.
Abstract For pharmaceutical patent attorneys who are making decisions in areas such as Freedom to Operate (FTO), it can be time-consuming to find all relevant legal information related to a particular target or therapy. Search savvy and proactive patent analysts can assist in the decision making process by providing attorneys with reports that contain more decision-enabling information than merely the results of blast and keyword searches. Providing information in areas such as legal status, current patent claims, relevant prior art, IP portfolio, and competitive intelligence when necessary will provide the attorney with a better context in which to frame an issue. By doing basic scientific analysis on documents resulting from Blast and keyword searches to determine relevance to the FTO issue, patent analysts can provide attorneys with the necessary information to facilitate FTO decision making.
Biography Barbara Miller is currently a Patent and Scientific Analyst at the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, MA. Prior to joining Novartis in August 2009, she was an Information Scientist at Pfizer in both Groton, CT and Ann Arbor, MI. She has a PhD in Biological Sciences from Emory University in Atlanta, GA, a MS in Regulatory Affairs and Quality Assurance from Temple University, and a BS in Chemistry from Rhodes College in Memphis, TN..
Contact Information [email protected]
22 SPONSORS AFTERNOON SESSION
Improving FTO Patent Analysis- Focusing Results Using Scientific Analysis By Barbara Miller, Novartis
23 2011 PIUG Biotechnology Meeting
Afternoon Session
4:20 pm – 4:55 pm
Biologics - Searching Patent Classes at the USPTO, WIPO, EPO, and JPO
By James L. Grant
Abstract Corporate search protocols have been developed to comprehensively capture biotech and biosequence data within world patent and journal collections for all aspects of due diligence. The large growth of biotech patent specifications led the patent offices to develop classifications of their own. The primary purpose of classification systems is to facilitate the searching and retrieving of patent documents by patent offices and users. Classification systems are hierarchical in nature with main headings covering a general area of technology and sub-headings covering a given type of invention. The systems allow searchers to identify the classification areas in which the technology is assigned to Art Units within the respective Offices. After identifying potential classification areas from the index, the class schedules must be consulted to determine the best and most exact classification groups in which to search. USPTO, WIPO, EPO, and JPO classification systems exist and must be searched separately so that technical aspects of an invention, to which a patent document relates, can be classified completely. The classification systems may provide an excellent ‘front end’ to searching for macromolecules that contain peptides, sugars, chemical linkers, etc.; methods & platform technologies; and anitbodies. Further, the class systems may reveal dominating claims to genus or classes not revealed by word or by sequence. The United States Patent Classification To International Patent Classification Concordance will be discussed in light of the EPO and JPO classification schema.
Biography James Grant has a PhD in Chemistry and is registered to practice as a Patent Agent before the USPTO. He works as a Consultant in chemical and biotechnology research sectors most recently in patent portfolio review and patent research for SciMed Partners Inc. James has also participated in IP Forums for WIPO. He recently presented lectures in Tunis highlighting USPTO content along with others presenting patent content from WIPO and the EPO. James has worked in patent research at Pfizer, Inc. and Bristol-Myers Squibb.
Contact Information [email protected]
24 SPONSORS AFTERNOON SESSION
Biologics - Searching Patent Classes at the USPTO, WIPO, EPO, and JPO By James L. Grant
25 2011 PIUG Biotechnology Meeting
Attendees (sorted by name)
Alberts, Doreen Theravance, Inc. Sandvoss, Leah Pfizer Bellomy, Gregory Merck Shu, Zhifu ExxonMobil R&E Brown, Jim Fiz Karlsruhe Sprunger, Suzanne Carter, Paul Genentech, Inc. Spytek, Kim Novartis Inst Biomedical Celidonio, Ana Gusmao & Labrunie Research Cheng, Yugong Eli Lilly and Company Stolz, Lesley Sutro Biopharma, Inc. Coignard, Fanny Pfizer Sukman, Jesse IPMG, LLC Cummins, Gary Fiz-Karlsruhe, Inc. Tambling, Todd GenericsWeb Diaz, Ruben Genentech, Inc. Turner, Elyse Merck & Co., Inc. Duberman, Josh NIH Watters, Julie RWS Group Englert, Austin Questel Weiss-Nolen, Monica Sanofi Pasteur Falciola, Luca Genfit Wood, David Townsend & Townsend & Frey, Paul Search Technology, Inc. Crew Fuerstenberg, Sal Novartis Vaccines & Diag. Garcia, Maria Jones Day Ghosh, Rita Echo Solutions Pvt. Ltd Gieber, Lisa Internation Aids Vaccine Initiative Goshorn, Alice Bristol-Myers Squibb Grant, James SciMed Partners Grant, Jonathan Lexis Nexis Hoppe, Ken Chemical Abstracts Service Im, Nam-Hee Genentech, Inc. Keil, Christina Pfizer Kenney, Bill GenomeQuest, Inc. Lee, Diana Novartis Vaccines & Diag. Lewis, Michelle ZymoGenetics, Inc. Li, Juan Codexis, Inc. Louden, Diana ZymoGenetics, Inc. Malone, Kathy LexisNexis May, Margaret Genentech Medical Comm McBride, Matthew Chemical Abstracts Service Mcconnell, Christopher Abbott Biotherapeutics Melikian, Anita SciMed Partners Meng, Qin Amgen Miller, Barbara Novartis Mitchell, Steve TPR INternational Nawani, Ashish Evalueserve Nguyen, Dave USPTO Oen, Helen Eisai, Inc. Puiggali, Clement Tempus IP Rappaport, Matthew IP Checkups, Inc. Robidoux, Phil GenomeQuest, Inc. Saku, Takashi JPO
26 SPONSORS ATTENDEES
Attendees (sorted by company)
Abbott Christopher Mcconnell Search Technology. Paul Frey Amgen Qin Meng Sutro Biopharma, Inc. Lesley Stolz Bristol-Myers Squibb Alice Goshorn Tempus IP Clement Puiggali Chemical Abstracts Ken Hoppe Theravance, Inc. Doreen Alberts Chemical Abstracts Matthew McBride Townsend & Townsend & Crew David Wood Codexis, Inc. Juan Li TPR International Steve Mitchell Echo Solutions Pvt. Rita Ghosh USPTO Dave Nguyen Eisai, Inc. Helen Oen ZymoGenetics, Inc. Michelle Lewis Eli Lilly and Co Yugong Cheng ZymoGenetics, Inc. Diana Louden Evalueserve Ashish Nawani (no company listed) Suzanne Sprunger ExxonMobil R&E Zhifu Shu Fiz Karlsruhe Jim Brown Fiz Karlsruhe Gary Cummins Genentech, Inc. Margaret May Genentech, Inc. Ruben Diaz Genentech, Inc. Nam-Hee Im Genentech, Inc. Paul Carter GenericsWeb Todd Tambling Genfit Luca Falciola GenomeQuest, Inc. Bill Kenney GenomeQuest, Inc. Phil Robidoux Gusmao & Labrunie Ana Celidonio Int Aids Vaccine Initiative Lisa Gieber IP Checkups, Inc. Matthew Rappaport IPMG, LLC Jesse Sukman Jones Day Maria Garcia JPO Takashi Saku LexisNexis Jonathan Grant LexisNexis Kathy Malone Merck Gregory Bellomy Merck Elyse Turner NIH Josh Duberman Novartis Barbara Miller Novartis Biomedical Kim Spytek Novartis Vaccines Sal Fuerstenberg Novartis Vaccines Diana Lee Pfizer Christina Keil Pfizer Leah Sandvoss Pfizer Fanny Coignard Questel Austin Englert RWS Group Julie Watters Sanofi Pasteur Monica Weiss-Nolen SciMed Partners James Grant SciMed Partners Anita Melikian
27 2011 PIUG Biotechnology Meeting
Patent Information Users Group, Inc. The International Society for Patent Information
About PIUG The Patent Information Users Group, Inc. (PIUG) – The International Society for Patent Information is a not-for-profit organization for individuals having a professional, scientific or technical interest in patent information. The Patent Information Users Group (PIUG) was established in 1988. The objective of the group was to create a forum to discuss issues and concerns relevant to the patent searcher community. PIUG promotes the importance of intellectual property, especially patent publications, and most specifically, the computerized patent databases. Since 1988, PIUG has worked with intellectual property database producers and vendors to maintain and to improve the quality of their product from the customer, or user, perspective. The mission of PIUG is to support, assist, improve and enhance the success of patent information professionals through leadership, education, communication, advocacy and networking. Through this international forum and discussion, we also promote and improve the retrieval, analysis and dissemination of patent information. PIUG has over 700 active members representing 27 countries including the United States. The largest concentration of members is from the USA, Europe and Japan. PIUG members are patent attorneys, patent agents, licensing professionals, patent information researchers, patent information vendors, and patent information and documentation experts from the U.S. and abroad. We have nearly 300 patent information professionals who do patent searching for corporations, over 100 patent information consultants, over 80 patent information professionals who do patent searching for law firms, and about 20 searchers based in academic institutions. We are employed in performing patentability, freedom-to-practice, and validity patent searches for Fortune 500 / multinational companies, leading universities and major IP law firms. In recent years, PIUG members have also engaged in patent information analysis as a strategic innovation tool. PIUG has an active Discussion Forum that is featured on the PIUG wiki, a global collaborative tool with nearly 1000 subscribers world-wide, and produces a newsletter twice a year. In addition, we have presence in professional and social networking channels, such as LinkedIn and Twitter. The PIUG newsletter contains members’ articles, salary survey results, search tips, meeting trip reports, and information on patent database vendor and producer developments.
Membership Information Membership is based on the calendar year. Renewals after October 1 are effective until December 31 of the following year. Effective January 1, 2010, the one-year membership fee is $50 (US) and includes the member benefits listed below. A discounted annual membership fee of $25 (US) is available for full-time students, full-time retirees and those unemployed at the time of renewal. We also offer a discounted membership fee to individuals from lower income, emerging countries (as defined by the World Bank). Membership benefits include: • PIUG Membership Directory (Members-only site). • Reduced registration fees for PIUG conferences: the PIUG Annual Conference (May), PIUG Boston Biotech meeting (February) and PIUG Northeast Conference (October). • Access to Annual, Biotech, and Northeast Conference Proceedings (Members-only wiki access). • PIUG Newsletter and Newsletter Archive Access (the cover page of the most recent issue is available to all). • PIUG Salary Survey and Access to Previous Surveys (Members-only wiki access). • Enhanced functionality on PIUG wiki. • Ongoing professional training through conference venues and sponsors. • Access to the PIUG LinkedIn group.
For more information about PIUG please visit www.piug.org and wiki.piug.org 28 2011PIUGconf_7-25x9-5.pdf 1 10/1/10 7:45 AM
SAVE THESE
The International Society for Patent Information
Member Benefits: DATES
PIUG Membership Directory (Members-only site) PIUG 2011 Annual Meeting Reduced registration fees for PIUG May 21-26, 2011 conferences Best Practices Beyond Free-Text: The Value of
Reduced subscription rates such as Indexing and Classification When Searching for World Patent Information and Analyzing Patents magazine Hyatt Regency, Cincinnati, OH
Reduced registration for other meetings such as the IPWARE SUMMIT
Members-only access to Annual, Biotech, and Northeast Conference Proceedings
PIUG Newsletter and Newsletter Archive Access
Members-only access to PIUG Salary Survey and Previous Surveys
Enhanced functionality on PIUG wiki
Ongoing professional training through conference venues and sponsors
Access to the PIUG LinkedIn group
www.PIUG.org P: 414-908-4955 7044 S. 13th St. Oak Creek, WI 53154 Hyatt in Cincinnati n We’re o
s
m
a
d
A
a
h t r e
B
y b
o t o h p
” i t s A focused! & e v li O “
BizInt Smart Charts for Patents 3.4
BizInt Smart Charts for Patents helps you create reports combining search results from gene sequence databases (GenomeQuest and USGENE on STN) with results from patent and non-patent literature Congratulations to Remy – searches. Dachshund Club of America Triathlon Dog of 2010! BizInt Smart Charts for Patents Version 3.4 adds: • support for LexisNexis TotalPatent and Orbit.com, • features to make it easier to edit reports, and • more sources for full-text links. We’re also working hard on BizInt Smart Charts Reference Rows™, with an exciting new capability to combine data from different records into a single “Reference Row” row in your report.
Visit our website www.bizcharts.com to learn more about the latest developments in BizInt Smart Charts for Patents!
650 North Costello Pl Orange, CA 92869 USA 1.714.289.1000 TEL 1.714.744.1316 FAX www.bizcharts.com Silver Sponsor of the PIUG Biotechnology Meeting
For more information, please visit our website - www.bizcharts.com